Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy.
Al Zaki A, Feng L, Watson G, Ahmed SA, Mistry H, Nastoupil LJ, Hawkins M, Nair R, Iyer SP, Lee HJ, Steiner RE, Flowers CR, Shpall EJ, Kebriaei P, Neelapu SS, Westin JR, Strati P.
Al Zaki A, et al. Among authors: nastoupil lj.
Blood Adv. 2022 May 10;6(9):2867-2871. doi: 10.1182/bloodadvances.2021006715.
Blood Adv. 2022.
PMID: 35015825
Free PMC article.